Cargando…
Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations
SGLT2 (sodium-glucose cotransporter 2) inhibitors are a new class of antihyperglycaemic drugs that act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes mellitus type 2 and their cardiovascular and renal safety have been extensively investigated and confir...
Autores principales: | Klen, Jasna, Dolžan, Vita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466905/ https://www.ncbi.nlm.nih.gov/pubmed/34575958 http://dx.doi.org/10.3390/ijms22189800 |
Ejemplares similares
-
SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation
por: Klen, Jasna, et al.
Publicado: (2023) -
Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors
por: Klen, Jasna, et al.
Publicado: (2022) -
Genetic variability in sodium-glucose cotransporter 2 influences glycemic control and risk for diabetic retinopathy in type 2 diabetes patients
por: Klen, Jasna, et al.
Publicado: (2020) -
The Role of Genetic Factors and Kidney and Liver Function in Glycemic Control in Type 2 Diabetes Patients on Long-Term Metformin and Sulphonylurea Cotreatment
por: Klen, Jasna, et al.
Publicado: (2014) -
NLRP3 Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes Patients
por: Klen, Jasna, et al.
Publicado: (2015)